4//SEC Filing
Shetzline Michael 4
Accession 0001209191-23-014280
CIK 0001446847other
Filed
Feb 28, 7:00 PM ET
Accepted
Mar 1, 6:21 PM ET
Size
11.3 KB
Accession
0001209191-23-014280
Insider Transaction Report
Form 4
Shetzline Michael
SVP, CMO, Head-Res&Drug
Transactions
- Sale
Class A Common Stock
2023-02-27$11.41/sh−2,322$26,494→ 271,440 total - Sale
Class A Common Stock
2023-02-27$11.41/sh−7,146$81,536→ 273,762 total - Sale
Class A Common Stock
2023-02-28$11.31/sh−7,438$84,124→ 264,002 total - Sale
Class A Common Stock
2023-02-28$11.31/sh−2,416$27,325→ 261,586 total
Footnotes (4)
- [F1]The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.29 to $11.53, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F3]The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based restricted stock units granted on February 27, 2020 and April 24, 2020. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
- [F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.26 to $11.38, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Documents
Issuer
IRONWOOD PHARMACEUTICALS INC
CIK 0001446847
Entity typeother
Related Parties
1- filerCIK 0001808509
Filing Metadata
- Form type
- 4
- Filed
- Feb 28, 7:00 PM ET
- Accepted
- Mar 1, 6:21 PM ET
- Size
- 11.3 KB